Reference is made to the stock exchange notice of Aqua Bio Technology ASA ("ABT" or the "Company") published on 14 February 2019 regarding independent subscription rights issued by the Company ("Warrants").

Each Warrant gives the holder a right to subscribe for one (1) share in the Company at a subscription price of NOK 2.50 per share.  The exercise period for the Warrants commenced on 30 June 2019 and expires on 1 September 2019. Warrants that are not exercised within the end of 1 September 2019 will lapse automatically without compensation to the holder.

Espen Dahl (including associated companies), which is a related party to Board member Kristin Aase, have exercised 400,000 Warrants for an amount of NOK 1,000,000.

If no other Warrants are exercised before the end of the exercise period, and taking into account the exercise of Warrants disclosed in  a stock exchange notice of 28 August 2019, Espen Dahl and related parties will own 1,413,265 shares (corresponding to 9.2% of the currently outstanding shares, and including the total number of exercised Warrants).

For further information, please contact Espen Kvale, acting CEO, telephone +47 916 28 092 or espen.kvale@aquabiotech.no

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.